Gujral told CNBC-TV18, "Glenmark continues to surprise on the upside. I think Rs 750 is quite likely out there. Some of the midcap pharma stocks like Orchid , they are looking very positive, and there you could expect levels of Rs 320. Sun Pharma also is looking good; we are expecting Rs 1350-1360 as a target. So midcap pharma along with midcap tech is looking much better."